期刊文献+

心肌血运重建出院患者随访现况研究 被引量:2

Cross- sectional Study on the Follow-up of Myocardial Revascularization Patients after Discharge
下载PDF
导出
摘要 目的:了解心肌血运重建出院患者的随访现况,并探讨在手术实施医院随访者与非手术实施医院随访者的依从性、安全性及经济性。方法选取2013年度在首都医科大学附属北京安贞医院出院的心肌血运重建患者1925例,其中经皮冠状动脉介入术(PCI)1534例,冠状动脉旁路移植术(CABG)391例。根据患者随访机构不同分为手术实施医院组与非手术实施医院组,手术实施医院组数据来源于本院医院信息系统( HIS),包括门诊及再住院信息;非手术实施医院组数据来源于北京市医保数据,包括门诊与再住院信息。通过随访率、随访次数及人均随访次数指标对不同随访时间、不同随访地点及不同手术方式的人群随访现况进行描述。并记录患者二级预防药物服用率、主要不良心血管事件( MACE)发生率和门诊费用及住院费用。结果1925例患者平均随访率为94.27%,随访次数共计41774次,人均22次。手术实施医院组1011例(52.52%),平均随访率为94.49%,随访次数共计19834次,人均20次;非手术实施医院组914例(47.48%),平均随访率为94.04%,随访次数共计21940次,人均24次。PCI患者随访率为94.50%,随访次数共计32984次,人均22次;CABG患者平均随访率为93.39%,随访次数共计8790次,人均23次。患者阿司匹林服用率为71.90%(1384/1925),氯吡格雷服用率(仅为 PCI 患者的服用率)为86.11%(1321/1534),他汀类药物服用率为77.40%(1490/1925),β-受体阻滞剂服用率为60.16%(1158/1925),血管紧张素转化酶抑制剂(ACEI)/血管紧张素受体阻滞剂(ARBs)服用率为43.43%(836/1925),双联抗血小板药物服用率(指同时服用阿司匹林和氯吡格雷,仅为PCI患者的服用率)为67.34%(1033/1534)。手术实施医院组和非手术实施医院组他汀类药物、ACEI/ARBs服用率比较,差异均无统计学意义( P﹥0.05);手术实施医院组氯吡格雷服用率低于非手术实施医院组,阿司匹林、β-受体阻滞剂、双联抗血小板药物服用率均高于非手术实施医院组(P﹤0.05)。患者在随访期间MACE共发生149例,发生率为7.74%。手术实施医院组MACE发生率为7.22%(73/1011),非手术实施医院组MACE发生率为8.32%(76/914)。两组主要终点事件和次要终点事件发生率比较,差异均无统计学意义(χ^2=0.429,P=0.513;χ^2=0.366,P=0.545)。患者门诊费用(10166±3198)元,住院费用11665(6862,35185)元。手术实施医院组门诊费用高于非手术实施医院组(t=9.428,P﹤0.001);手术实施医院组和非手术实施医院组住院费用比较,差异无统计学意义( z=-0.536,P﹥0.050)。结论心肌血运重建出院患者平均随访率为94.27%,人均22次/年。52.52%出院患者继续于手术实施医院进行随访,规范服用二级预防药物比例总体较好,但β-受体阻滞剂与ACEI/ARBs的依从性有待进一步提升,MACE发生率为7.74%。非手术实施医院需进一步强化随访知识,提升其药物治疗的依从性及安全性,分流随访人群,使医疗资源更合理利用。 Objective To understand the follow-up situations of myocardial revascularization patients after discharge and discuss the compliance,safety and economic efficiency. Methods 1 925 cases of myocardial revascularization patients discharged from Beijing Anzhen Hospital, Capital Medical University in 2013 were selected, including 1 534 cases of percutaneous coronary intervention(PCI)and 391 cases of coronary artery bypass grafting(CABG). According to follow-up institutions,patients were divided into implementation of operation hospital group and non-implementation of operation hospital group. The data of implementation of operation hospital group were collected from the HIS of this hospital,including outpatient and re-hospitalization information. The data of non-implementation of operation hospital group were collected from the data of Beijing medical insurance,including outpatient and re - hospitalization information. The current situations of follow - up of populations at different follow-up times,sites and operation method were described through indexes of follow-up rate,follow-up frequency and average follow-up frequency. Secondary prevention drug taking rate,incidence rate of major adverse cardiac events( MACE),outpatient fees and hospitalization expenses of patients were recorded. Results The average follow-up rate of 1 925 cases of patients was 94. 27%. The frequency of follow-up totaled 41 774 times,with an average of 22 times. The implementation of operation hospital group had 1 011 cases ( 52. 52%) with an average follow - up rate of 94. 49%. The frequency of follow-up totaled 19 834 times,with an average of 20 times. The non-implementation of operation hospital group had 914 cases(47. 48%)with an average follow -up rate of 94. 04%. The frequency of follow -up totaled 21 940 times of follow-up,with an average of 24 times. The follow -up rate of PCI patients was 94. 50% and the frequency of follow -up totaled 32 984 times,with an average of 22 times. The follow-up rate of CABG patients was 93. 39% and the frequency of follow-up totaled 8 790 times,with an average of 23 times. The taking rate of aspirin was 71. 90%(1 384/1 925). The taking rate of clopidogrel(only the taking rate of PCI patients)was 86. 11%(1 321/1 534). The taking rate of statins was 77. 40%(1 490/1 925). The taking rate ofβ-receptor blocker was 60. 16%(1 158/1 925). The taking rate of ACEI/ARBs was 43. 43%(836/1 925). The taking rate of dual anti -platelet( which meant to take aspirin and clopidogrel at the same time,only the taking rate of PCI patients) was 67. 34%(1 033/1 534). The implementation of operation hospital group and non-implementation of operation hospital group were compared in the taking rates of statins and ACEI/ARBs,the differences had no statistical significance(P﹥0. 05). The taking rate of clopidogrel in implementation of operation hospital group was lower than that in non-implementation of operation hospital group and taking rates of aspirin,β-receptor blocker and dual anti-platelet in implementation of operation hospital group were higher than those in non-implementation of operation hospital group (P﹤0. 05). 149 cases of patients appeared MACE during the follow -up period,with the incidence rate of 7. 74%. The incidence rate of MACE in implementation of operation hospital group was 7. 22%(73/1 011) and the incidence rate of MACE in non-implementation of operation hospital group was 8. 32% ( 76/914 ). The occurrence rates of primary endpoint and secondary endpoint were compared and the difference had no statistical significance(χ^2 =0. 429,P=0. 513;χ^2 =0. 366,P=0. 545). The average outpatient fee was(10 166 ± 3 198)yuan and the hospitalization expenses per capita was 11 665 (6 862,35 185) yuan. The average outpatient fee of implementation of operation hospital group was higher than that of non-implementation of operation hospital group and the difference had statistical significance ( t = 9. 428, P ﹤ 0. 001 ). The hospitalization expenses of implementation of operation hospital group and non-implementation of operation hospital group were compared and the difference had no statistical significance(z= -0. 536,P﹥0. 050). Conclusion The average follow-up rate of myocardial revascularization patients after discharge is 94. 27%, with an average of 22 times/year. 52. 52% of the discharged patients were continuously followed up in the implementation of operation hospital,with better total ratio of normatively taking secondary prevention drugs,but the compliance of ACEI/ARBs drugs and β -receptor blocker needed to be improved further,with the incidence rate of MACE of 7. 74%. Non -implementation of operation hospital needs to further strengthen follow-up knowledge,improve the compliance and safety of drug treatment,decentralize follow-up population so as to make useful utilization of medical resources.
出处 《中国全科医学》 CAS CSCD 北大核心 2016年第26期3210-3214,共5页 Chinese General Practice
基金 北京市保健专项资金科研项目(京15-05号)
关键词 心肌血管重建术 随访研究 现况研究 Myocardial revascularization Follow-up studies Cross-sectional studies
  • 相关文献

参考文献9

  • 1韩雅玲.中国经皮冠状动脉介入治疗指南2012(简本)[J].中华危重症医学杂志(电子版),2012,5(3):18-26. 被引量:117
  • 2WINDECKER S, KOLH P, ALFONSO F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio -Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular [ J]. Eur Heart J, 2014, 35 (37): 2541 -2619.
  • 3陈伟伟,高润霖,刘力生,朱曼璐,王文,王拥军,吴兆苏,李惠君,郑哲,蒋立新,胡盛寿.《中国心血管病报告2014》概要[J].中国循环杂志,2015,30(7):617-622. 被引量:797
  • 4GOEL K, LENNON R J, TILBURY R T, et al. Impact of cardiac rehabilitation on mortality and cardiovascular events after percutaneous coronary intervention in the community [ J]. Circulation, 2011, 123 (21) : 2344 -2352.
  • 5HAMMILL B G, CURTIS L H, SCHULMAN K A, et al. Relationship between cardiac rehabilitation and long- term risks of death and myocardial infarction among elderly medicare beneficiaries [J]. Circulation, 2010, 121 (1): 63-70.
  • 6NEWBY L K, LAPOINTE N M, CHEN A Y, et al. Long - term adherence to evidence - based secondary prevention therapies in coronary artery disease [J]. Circulation, 2006, 113 (2): 203 -212.
  • 7MADDOX T M, CHAN P S, SPERTUS J A, et al. Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices: insights from the NCDR (National Cardiovascular Data Registry) [ J]. J Am Coil Cardiol, 2014, 63 (6) : 539 -546.
  • 8ROBERTS L, ANDRIANOPOULOS N, HARRIES I, et al. Long - term outcomes and predictors of death and MACE following PCI: insights from the MIG registry [ J]. Heart Lung Circ, 2010, 19 (Suppl 2) : S139.
  • 9ARTURO G, MICHELE P, NICOLA C, et al. Synergy between direct coronary stenting technique and use of the novel thin strut cobalt chromium SkylorTM stent: the MACE in follow up patients treated with Skylorstcnt [MILES Study] [J]. Curr Cardiol Rev, 2012, 8 (1): 6-13.

二级参考文献6

  • 1Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC) and the European Association for Cardio-Thoracic Surgery(EACTS),European Association for Percutaneous Cardiovascular Interventions(EAPCI),Wijns W. Guidelines on myocardial revascularization[J].European Heart Journal,2010.2501-2555.
  • 2Levine GN,Bates ER,Blankenship JC. 2011ACCF/AHA/SCAI guideline for percutaneous coronary intervention:a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions[J].Circulation,2011.e574-e651.
  • 3Hillis LD,Smith PK,Anderson JL. 2011 ACCF / AHA guideline for coronary artery bypass graft surgery.A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines.developed in collaboration with the American Association for Thoracic Surgery,Society of Cardiovascular Anesthesiologists,and Society of Thoracic Surgeons[J].Journal of the American College of Cardiology,2011.e123-e210.
  • 4Nashef SA,Roques F,Michel P. European system for cardiac operative risk evaluation(EuroSCORE)[J].European Journal of Cardio-Thoracic Surgery,1999.9-13.
  • 5Serruys PW,Morice MC,Kappetein AP. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease[J].New England Journal of Medicine,2009.961-972.
  • 6Peterson ED,Dai D,DeLong ER. Contemporary mortality risk prediction for percutaneous coronary intervention:results from 588,398 procedures in the National Cardiovascular Data Registry[J].J Am Coll Cardi01,2010.1923-1932.

共引文献911

同被引文献35

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部